...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British Journal of Nutrition >Bovine lactoferrin ingestion protects against inflammation via IL-11 induction in the small intestine of mice with hepatitis.
【24h】

Bovine lactoferrin ingestion protects against inflammation via IL-11 induction in the small intestine of mice with hepatitis.

机译：摄入牛乳铁蛋白可通过肝炎小鼠小肠中的IL-11诱导防止炎症。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Accumulating evidence suggests that orally ingested lactoferrin protects against inflammation. To assess the efficacy of orally administered bovine lactoferrin (bLF) against hepatitis and to identify the underlying mechanism, in the present study, we used four mouse models of hepatitis induced by D-galactosamine (GalN), carbon tetrachloride (CCl4), GalN plus lipopolysaccharide (LPS) and zymosan plus LPS. Intraperitoneal (i.p.) injection of GalN (500 mg/kg body weight) in mice treated with bovine serum albumin (BSA) for 14 d significantly increased serum aspartate aminotransferase (AST) concentrations compared with the untreated mice. However, orally administered bLF reduced AST concentrations compared with BSA treatment. In mice that received a single injection (0.4 ml/kg) and twice-weekly injections (0.08 ml/kg) of CCl4 for 24 weeks and pretreated with bLF for 14 d and 24 weeks, respectively, significantly suppressed alanine aminotransferase and AST concentrations were observed compared with the BSA-treated control. Oral administration of bLF for 14 d before i.p. injection of LPS (5 mg/kg) plus GalN (1 g/kg) significantly improved the survival rate. In mice that received intravenous injection of zymosan (25 mg/kg) and LPS (15 micro g/kg) at 7 d intervals, bLF reduced the elevation of AST concentrations and enhanced the production of IL-11 and bone morphogenetic protein 2 in the small intestine compared with the BSA-treated control. To evaluate the effects of IL-11, we used IL-11 receptor alpha -null mice treated with GalN, CCl4 and zymosan plus LPS. In this group, the activity of bLF was not significantly different from that of BSA. These data indicate that orally ingested bLF enhances the expression of IL-11 in the small intestine and up-regulates protective activity in mice with hepatitis.
机译：越来越多的证据表明，口服摄取的乳铁蛋白可预防炎症。为了评估口服牛乳铁蛋白（bLF）对肝炎的疗效并确定其潜在机制，在本研究中，我们使用了D-半乳糖胺（GalN），四氯化碳（CCl 4 ），GalN加脂多糖（​​LPS）和酵母聚糖加LPS。与未治疗的小鼠相比，在用牛血清白蛋白（BSA）处理14天的小鼠中腹膜内（i.p.）注射GalN（500 mg / kg体重）显着提高了血清天冬氨酸转氨酶（AST）的浓度。然而，与BSA治疗相比，口服bLF降低了AST浓度。在接受CCl 4 单次注射（0.4 ml / kg）和每周两次注射（0.08 ml / kg）的小鼠中，分别接受24周和bLF预处理分别为14 d和24周，与BSA处理的对照相比，观察到显着抑制的丙氨酸氨基转移酶和AST浓度。腹腔注射bLF持续14天。注射LPS（5 mg / kg）加GalN（1 g / kg）可以显着提高生存率。在间隔7 d接受静脉注射zymosan（25 mg / kg）和LPS（15 micro g / kg）的小鼠中，bLF降低了AST浓度的升高，并增强了大鼠体内IL-11和骨形态发生蛋白2的产生。与经BSA处理的对照组相比，小肠较弱。为了评估IL-11的作用，我们使用了GalN，CCl 4 和zymosan加LPS处理的IL-11受体alpha无效小鼠。在该组中，bLF的活性与BSA的活性无显着差异。这些数据表明，口服摄入的bLF可以增强小肠中IL-11的表达，并上调肝炎小鼠的保护活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号